ERITROPOYETINA HUMANA MODIFICADA

Una eritropoyetina humana modificada con un tiempo de vida media en plasma aumentado, con actividad eritropoyetica menor al 0,5 % en relacion a una eritropoyetina nativa, que mantiene su capacidad neuroprotectora y neuroplastica, que comprende la mutacion de al menos uno de los sitios de union al receptor homodimerico o heterodimerico mediante la incorporacion de sitios consenso de N-glicosilacion A modified human erythropoietin with an increased plasma half-life, with an erythropoietic activity of less than 0.5% in relation to a native erythropoietin, which maintains the neuroprotective and neuroplastic capacity, which comprises the mutation of at least one of the binding sites the homodimeric or heterodimeric receptor by incorporating consensus sites for N-glycosylation.